The high prevalence of thermolabile 5-10 methylenetetrahydrofolate reductase (MTHFR) in Italians is not associated to an increased risk for coronary artery disease (CAD)

Thrombosis and Haemostasis

Volumn 79, Issue 4, 1998, Pages 727-730

  Abbate, Rosanna ^a   Sardi, Iacopo ^a   Pepe, Guglielmina ^a,b   Marcucci, Rossella ^a   Brunelli, Tamara ^a   Prisco, Domenico ^a   Fatini, Cinzia ^a   Capanni, Monia ^a   Simonetti, Ignazio ^a   Gensini, Gian Franco ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); MUTANT PROTEIN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY RISK; GENE FREQUENCY; GENE MUTATION; HOMOZYGOTE; HUMAN; MAJOR CLINICAL STUDY; POPULATION GENETICS; PRIORITY JOURNAL; TRANSLUMINAL CORONARY ANGIOPLASTY;

EID: 0031969688     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1615053     Document Type: Article

References (25)

1. Boushey CJ, Beresford SSA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocyst(e)ine as a risk factor for vascular disease: probable benefits of increasing folic acid intakes. JAMA 1995; 274: 1049-57.
2. Graham M. The European Concerted Action Project. Plasma homocysteine as a risk factor for vascular disease. JAMA 1997; 277: 1775-89.
3. Kang SS, Wong PWK, Susmano A, Sora J, Norusis M, Ruggie N. Thermolabile methylenetetrahydrofolate reductase: an inherited risk factor for coronary artery disease. Am J Hum Genet 1991; 48: 536-45.
4. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews R., Boers GJH, van den Heuvel L., Rosen R. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995; 10: 111-3.
5. Kang SS, Passen EL, Ruggie N, Wong PWK, Sora J. Thermolabile defect of methylenetetrahydrofolate reductase in coronary artery disease. Circulation 1993; 88: 1463-9.
6. Engbersen AMT, Franken DG, Boers GHJ, Stevens EMB, Trijbels FJM, Blom HJ. Thermolabile 5,10-methylenetetrahydrofolate reductase as a cause of mild hyperhomocysteinemia. Am J Hum Genet 1995; 56: 142-50.
7. Arruda VR, von Zuben PM, Chiaparini LC, Annichino-Bizzacchi JM, Costa FF. The Mutation Ala677→Val in the methylene tetrahydrofolate reductase gene: a risk factor for arterial disease and venous thrombosis. Thromb Haemost 1997; 77: 818-21.
8. Morita H, Taguchi J, Kurihara H, Kitaoka M, Kaneda H, Kurihara Y, Maemura K, Shindo T, Minamino T, Ohno M, Yamaoki K, Ogasawara K, Aizawa T, Suzuki S, Yazaki Y. Genetic polymorphism of 5,10-methylentetrahydrofolate reductase (MTHFR) as a risk factor for coronary artery disease. Circulation 1997; 95: 2032-6.
9. Kluijtmans LAJ, van den Heuvel LPWJ, Boers GHJ, Frosst P, Stevens EMB, van Oost BA, den Heijer M, Trijbels FJH, Rozen R, Blom H. Molecular genetic analysis in mild hyperhomocysteinemia: a common mutation in the methylentetrahydrofolate reductase gene is a genetic risk factor for cardiovascular disease. Am J Hum Genet 1996; 58: 35-41.
10. Wilcken DEL, Wang XL, Sim AS, McCredie M. Distribution in healthy and coronary populations of the methylentetrahydrofolate reductase (MTHFR) C677T mutation. Arterioscler Thromb Vasc Biol 1996; 16: 878-82.
11. van Bockxmeer FM, Mamotte CDS, Vasikaran SD, Taylor RR. Methylenetetrahydrofolate reductase gene and coronary artery disease. Circulation 1997; 95: 21-4.
12. Brugada R, Marian AJ. A common mutation in methylenetetrahydrofolate reductase gene is not a major risk of coronary artery disease or myocardial infarction. Atherosclerosis 1997; 128: 107-12.
13. Dotter CT, Judkins MP. Transluminal treatment of arteriosclerotic obstruction: description of a new technique and a preliminary report of its application. Circulation 1964; 30: 654-70.
14. De Groote P, Bauters C, Mc Fadden E, Lablanche JM, Leroy F, Bertrand ME. Local lesion-related factors and restenosis after coronary angioplasty. Circulation 1995; 91: 968-72.
15. Sambrook J, Fritsch EF, Maniatis P. Molecular cloning. A laboratory manual. Cold Spring Harbour Laboratory Press, NY 1989.
16. Tunstall-Pedoe H, Kuulasmaa K, Amouyel P, Arveiler D, Rajakangas AM, Pajak A. Myocardial infarction and coronary deaths in the World Health Organization MONICA Project. Circulation 1994; 90: 583-612.
17. Renaud S, De Lorgeril M. Wine, alcohol, platelets, and the French paradox for coronary artery disease. Lancet 1992; 339: 1523-6.
18. Missiaglia E, Tosetto A, Rodeghiero F. The VITA project: risk of venous thromboembolism and C677T mutation of the MTHFR gene (abstract). Thromb Haemost 1997; (suppl.): 393.
19. De Stefano V, Chiusolo P, Paciaroni K, Casarelli I, Serra FG, Bizzi B, Leone G. Prevalence of factor V 1691 C to A and methylentetrahydrofolate reductase 677C to T mutated genes in patients with venous thrombosis (abstract). Thromb Haemost 1997; (suppl): 569.
20. Grandone E, Margaglione M, Calaizzo D, Cappucci G, Paladini D, Martinelli P, Montanaro S, Pavone G, Di Minno G. Factor V Leiden, C>T MTHFR polymorphism and genetic susceptibility to preeclampsia. Thromb Haemost 1997; 77: 1052-4.
21. Annuario Statistico Italiano. 1996 ISTAT.
22. Jacques P, Bostom A, Williams R. Relation between folate status, a common mutation in methylenetetrahydrofolate reductase and plasma homocysteine concentrations. Circulation 1996; 93: 7-9.
23. Mc Andrew P, Brandt JT, Pearl DK, Prior TW. The incidence of the gene for thermolabile methylene tetrahydrofolate reductase in African Americans. Thromb Res 1996; 83: 195-8.
24. Van der Put NMJ, Eskes AC, Blom HJ. Is the common 677 C → T mutation in the 5-10 methylenetetrahydrofolate reductase gene a risk factor for neural tube defects? A meta-analysis. Q J Med 1997; 90: 111-5.
25. Whitehead AS, Gallagher P, Mills JL, Kirke PN, burke H, Molloy AM, Weir DG, Shields DC, Scott JM. A genetic defect in 5-10 methylenetetrahydrofolate reductase in neural tube defects. Q J Med 1995; 88: 763-6.